Precigen, Inc. (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.
The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products. By using a modular receptor system, OmniCAR T cells can be retargeted against multiple tumor antigens through the administration of different adaptor molecules. In addition, Precigen’s ActoBiotics platform engineers live bacterial strains to deliver therapeutic payloads at disease sites, offering a novel route to treat gastrointestinal and other localized disorders.
Precigen’s clinical pipeline includes several early- to mid-stage programs. In oncology, the company is evaluating OmniCAR candidates targeting hematologic malignancies and solid tumors. The ActoBiotics pipeline features programs for inflammatory bowel disease and metabolic disorders. Precigen also maintains research collaborations and licensing partnerships aimed at expanding the utility of its gene control and vector technologies across diverse therapeutic areas.
Originally founded in 1998 as Intrexon Corporation, the company rebranded as Precigen in 2020 to reflect its strategic focus on precision genetic medicine. Headquartered in Germantown, Maryland, Precigen operates research and manufacturing sites in the United States and Europe. Under the leadership of President and CEO Helen Sabzevari, PhD, the company continues to build its pipeline and advance next-generation therapies toward regulatory milestones and commercialization.
AI Generated. May Contain Errors.
